Myriad Genetics Is Maintained at Neutral by UBS
Myriad Genetics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and Myriad Genetics (MYGN)
J.P. Morgan Maintains Myriad Genetics(MYGN.US) With Sell Rating, Cuts Target Price to $12
Raymond James Maintains Myriad Genetics(MYGN.US) With Buy Rating, Cuts Target Price to $19
Piper Sandler Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $14
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $16
Hold Rating on Myriad Genetics Amid Leadership Transition and Adjusted Revenue Expectations
Myriad Genetics Analyst Ratings
Craig-Hallum Initiates Coverage On Myriad Genetics With Buy Rating, Announces Price Target of $29
Craig-Hallum Initiates Myriad Genetics(MYGN.US) With Buy Rating, Announces Target Price $29
Myriad Genetics Is Maintained at Neutral by Piper Sandler
Piper Sandler Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $14
Myriad Genetics Analyst Ratings
Goldman Sachs Maintains Myriad Genetics(MYGN.US) With Buy Rating, Cuts Target Price to $18
Leerink Partners Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $18
Leerink Partners Sticks to Their Hold Rating for Myriad Genetics (MYGN)
Myriad Genetics Analyst Ratings
Stephens & Co. Reiterates Equal-Weight on Myriad Genetics, Maintains $20 Price Target
BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Maintains Target Price $13